New information counsel that GLP-1 remedy may cut back metastatic development in sure cancers, in accordance with findings that shall be offered on the 2026 American Society of Scientific Oncology’s annual assembly subsequent week. Metastatic development is the unfold of most cancers from its unique website to extra distant organs or tissues.
The analysis, which has not been revealed in a peer-reviewed journal as of this reporting, was carried out by the Cleveland Clinic and led by Dr. Mark Orland, who’s affiliated with the Taussig Most cancers Institute and can current the findings on the ASCO assembly.
What the research discovered was that GLP-1 medication appeared to have made a discount in most cancers development in sufferers who had been additionally recognized with Kind 2 diabetes or weight problems, when in comparison with different sufferers who had been taking DPP-4, Orland informed HuffPost. DPP-4 inhibitors, reminiscent of Januvia, Onglyza, Tradjenta and Nesina, are oral drugs used to deal with Kind 2 diabetes by serving to the physique launch insulin after meals.
Researchers additionally discovered that some most cancers cells had excessive ranges of GLP-1 receptors, which had been related to a 33% decrease threat of loss of life amongst sufferers taking the remedy, suggesting that GLP-1s may very well be attacking most cancers cells instantly.
“Over half of the GLP-1 customers in that cohort took the drug concurrently with lively anti-cancer systemic therapies like cytotoxic chemotherapy or immunotherapy,” Dr. Marcin Chwistek, chief of the Supportive Oncology and Palliative Care Program at Fox Chase Most cancers Heart and knowledgeable at ASCO, informed HuffPost.
Nevertheless, the research doesn’t verify that GLP-1 instantly kills any tumor cells, and since the evaluation was observational, the outcomes don’t totally show that GLP-1s instantly influence development. GLP-1 medication are usually not presently authorised for most cancers prevention, and shouldn’t be taken to attempt to decrease the danger of most cancers or to attempt to cease it from spreading.
The ASCO Put up famous that Orland holds consulting or advisory roles with Alexion Prescription drugs, Bristol Myers Squibb/Celgene, Geron and Novartis, and analysis funding from Alexion Prescription drugs, Apellis Prescription drugs, the Nationwide Institutes of Well being, Novartis and the Swedish Orphan Biovitrum.
GLP-1 medication, like Ozempic, Wegovy, Mounjaro and Zepbound, had been initially developed for Kind 2 diabetes, however at the moment are generally related to weight reduction. GLP-1s assist decrease glucose, cut back urge for food and physique weight, and decrease cardiovascular dangers, Meg Barbor, a senior medical journalist, wrote for the ASCO Put up.
Nevertheless, some GLP-1s have been authorised for well being advantages past diabetes and weight reduction: The Meals and Drug Administration authorised Wegovy to scale back the danger of great coronary heart illness in March 2024 and authorised Zepbound to deal with moderate-to-severe obstructive sleep apnea in December 2024.
There have been prior research that claimed GLP-1s may additionally cut back the danger of sure cancers, particularly these related to weight problems. Analysis offered on the 2026 ASCO Gastrointestinal Cancers Symposium in January claimed that GLP-1s “could have an additional advantage: serving to forestall colorectal most cancers.”
“Weight problems is unquestionably a threat issue for a lot of most cancers varieties,” Dr. Samyukta Mullangi, an oncologist and researcher with Tennessee Oncology and Thyme Care, informed HuffPost. “A lot of our endocrine therapies for breast and prostate most cancers particularly may cause weight acquire, which complicates survivorship.”
This connection between weight problems and most cancers varieties is why some researchers have begun investigating whether or not GLP-1s may help sufferers.
What did the Cleveland Clinic’s GLP-1 research discover?
Researchers on the Cleveland Clinic in contrast 12,112 sufferers with Stage 1 to three most cancers, with seven obesity-related cancers: Non-small cell lung most cancers (NSCLC), breast most cancers, colorectal most cancers, prostate most cancers, hepatocellular carcinoma (liver most cancers), pancreatic most cancers, and renal cell carcinoma. Half of the group took GLP-1 medication after getting recognized, whereas the opposite half used DPP-4 inhibitors.
To make sure that the separated teams had been comparable, the researchers matched sufferers on sure demographics, together with physique mass index, smoking historical past and prior most cancers therapies.
The sufferers taking GLP-1s had been “linked to decreased metastatic development in six of the seven malignancies studied, a sample the investigators mentioned could counsel a possible class impact,” Barbor reported.
In each most cancers case — apart from kidney most cancers — the sufferers taking GLP-1s had been much less prone to see development. (It’s not specified how lengthy the sufferers had been taking their respective medication earlier than the discount in metastasis was noticed by researchers.)
There have been “statistically important reductions” noticed in sufferers who had non-small cell lung most cancers, breast most cancers, colorectal most cancers and hepatocellular carcinoma, extra generally often called liver most cancers. (The variety of sufferers in every most cancers group different, Orland informed HuffPost, that means the outcomes for cancers with smaller pattern sizes could also be much less dependable than these for extra frequent cancers, like breast or colorectal. There was no organic motive discovered why the GLP-1s weren’t as efficient on prostate or pancreatic cancers.)
Amongst sufferers recognized with NSCLC, 22% taking DPP-4 inhibitors progressed to stage IV, in contrast with solely 10% taking GLP-1s. For breast most cancers sufferers, 20% of DPP-4 sufferers progressed, in comparison with 10% of GLP-1 sufferers. In colorectal most cancers, the development was 22% in comparison with 13%, respectively, and in liver most cancers sufferers, it was 28% versus 19%.
However not less than one researcher who carried out an identical research in July 2025 urges warning in regards to the comparator the Cleveland Clinic selected.
Dr. Jiang Bian, a professor of biostatistics and well being information science at Indiana College’s College of Drugs, was a part of a research through which they in contrast GLP-1s to DPP-4s and SGLT2 inhibitors — a category of medicine that block the kidneys from reabsorbing glucose again into the bloodstream.
“In our research … GLP-1 does assist [when compared to DPP-4s], however when evaluating to SGLT2, there isn’t any distinction,” Bian mentioned.
Nevertheless, Bian additionally notes that their research used Medicare claims information for comparisons moderately than a comparability group and lacked entry to sufferers’ respective physique mass index, in contrast to the Cleveland Clinic.
The Cleveland Clinic research was deliberately targeted solely on DPP-4, Orland mentioned.
“We selected DPP-4 extra so as a result of it was the least contentious of the group,” Orland mentioned, that means it’s much less seemingly than different diabetes medication to have its personal results on most cancers, which may skew the outcomes.
Extra analysis is critical earlier than GLP-1s could be dubbed a cancer-saving drug.
Research have discovered that GLP-1s may make it tougher for most cancers to develop within the physique by affecting blood sugar and insulin ranges, decreasing inner irritation, and supporting the physique’s immune cells, the American Most cancers Society mentioned in March.
“GLP-1 RAs have by no means been simply glucose-lowering medication,” Chwistek mentioned at a press convention on Thursday.
“Their anti-inflammatory and immune-modulatory properties have lengthy steered broader results. What’s new right here is the consistency throughout tumor varieties, and information this massive and this constant warrant a potential randomized trial.”
Orland emphasised that at no level will a most cancers affected person with no Kind 2 diabetes or weight problems analysis be informed to attempt GLP-1s.
“We don’t have sufficient analysis,” Orland mentioned. “It’s too early to behave on it.”
Orland expects to be concerned in future research to research additional how GLP-1s work together with particular most cancers tumors. Extra observational information are essential to conclude whether or not GLP-1s are the best choice, too, and Orland informed HuffPost he desires to discover different choices, like SGLT2.
“It’s undoubtedly too early to prescribe GLP-1s solely as a software for most cancers remedy or to forestall metastasis,” Chwistek mentioned. “Whereas seeing real-world information present a 38% to 50% discount in metastatic development throughout lung, breast, colorectal, and liver cancers is an extremely thrilling catalyst for analysis, it doesn’t immediately change normal oncological care.”
These findings are the start of additional analysis into what GLP-1s may do for some most cancers sufferers — not a conclusion, Orland mentioned.
Till then, for the tens of millions of most cancers sufferers who additionally occur to be taking GLP-1s, the query of whether or not the drug may be serving to them stays unanswered. For now.
